1	Identification of Genetic Loci Simultaneously Associated with Multiple Cardiometabolic
2	Traits
3	Alexis C. Wood, Ph.D. ¹ , Amit Arora MPH ² , Michelle Newell MS ² , Victoria L. Bland PhD ³ , Jin
4	Zhou PhD ⁴ , Nicola Pirastu, PhD ⁵ , Jose M. Ordovas, Ph.D ^{6,7} , Yann C. Klimentidis, Ph.D ^{2,8}
5	
6	¹ USDA/ARS Children's Nutrition Research Center, 1100 Bates Avenue, Houston, TX
7	² Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public
8	Health, University of Arizona, Tucson, AZ
9	³ Division of Geriatric Medicine, School of Medicine, University of Colorado Anschutz Medical
10	Campus, Aurora, CO
11	⁴ Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA
12	⁵ Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh,
13	Scotland
14	⁶ Nutrition and Genomics Laboratory, Jean Mayer U.S. Department of Agriculture Human
15	Nutrition Research Center on Aging, Tufts University, Boston, MA
16	⁷ IMDEA-Food, Madrid, Spain
17	⁸ BIO5 Institute, University of Arizona, Tucson, AZ
18	
19	Corresponding author: Alexis C. Wood, USDA/ARS Children's Nutrition Research Center - Rm
20	2036, 1100 Bates Avenue, Houston, TX 77030. Tel: 713-798-7055. Email:
21	LekkiWood@Gmail.com
22	
23	Word count: 2,706

It is made available under a CC-BY-NC-ND 4.0 International license .

- 24 Short title: GWAS of Cardiometabolic Traits
- 25 Subject terms: GWAS, Cardiometabolic Disease, Epidemiology, Risk Factors, Pleiotropy

26 Sources of Support

- 27 The authors would like to acknowledge support from the National Heart, Lung, and Blood
- 28 Institutes (R01-HL136528). Dr. Wood's role on this project was funded, in part, by USDA/ARS
- 29 cooperative agreement # 58-3092-5-001. The contents of this publication do not necessarily
- 30 reflect the views or policies of the U.S. Department of Agriculture, nor does mention of trade
- 31 names, commercial products, or organizations imply endorsement by the U.S. Government. The
- 32 funders had no role in study design, data collection and analysis, decision to publish, or
- 33 preparation of the manuscript.
- 34
- 35
- 36

- 38 Abbreviations:
- 39 ALT: alanine aminotransferase
- 40 BMI: body mass index
- 41 CARDIOGRAM: Coronary Artery Disease Genome-wide Replication And Meta-analysis
- 42 CAD: coronary artery disease
- 43 CMD: cardiometabolic disorders
- 44 CVD: cardiovascular disease
- 45 DIAGRAM: Diabetes Genetics Replication And Meta-analysis
- 46 DBP: diastolic blood pressure
- 47 GERA: Genetic Epidemiology Research on Adult Health and Aging cohort
- 48 GIANT: Genetic Investigation of Anthropometric Traits consortium
- 49 GLGC: Global Lipids Genetics Consortium
- 50 GWAS: genome-wide association studies
- 51 HbA1c: hemoglobin A1c
- 52 HDL-C: high-density lipoprotein cholesterol
- 53 LDL-C: low-density lipoprotein cholesterol
- 54 NHANES: National Health and Nutrition Examination Survey
- 55 PPFC: posterior probability of full colocalization
- 56 SBP: systolic blood pressure
- 57 T2D: type 2 diabetes
- 58 TGs: triglycerides
- 59 UK: United Kingdom
- 60 WHR: waist-to-hip-ratio
- 61 WHRadjBMI: waist-to-hip ratio adjusted for BMI

It is made available under a CC-BY-NC-ND 4.0 International license .

62 Abstract

64such as increased adiposity, hyperlipidemia, hypertension and compromised glucose control.65Many genetic loci have shown associations with individual CMD-related traits, but no66investigations have focused on simultaneously identifying loci showing associations across al67domains. We therefore sought to identify loci associated with risk across seven continuous68CMD-related traits.69Methods and Results: We conducted separate genome-wide association studies (GWAS) for70systolic and diastolic blood pressure (SBP/DBP), hemoglobin A1c (HbA1c), low- and high-71density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides72(TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels o73significance (N=145-333) for each trait, but only four loci (in/near VEGFA, GRB14-COBLL174 <i>KLF14</i> , and <i>RGS19-OPRL1</i>) were associated with risk across all seven traits (P<5×10 ⁻⁸). We75sought replication of these four loci in an independent set of seven trait-specific GWAS meta-76analyses. <i>GRB14-COBLL1</i> showed the most consistent replication, revealing nominally77significant associations (P<0.05) with all traits except DBP.78Conclusions: Our analyses suggest that very few loci are associated in the same direction of r79with traits representing the full spectrum of CMD features. We identified four such loci, and a80understanding of the pathways between these loci and CMD risk may eventually identify fact81that can be used to identify pathologic disturbances that represent broadly beneficial therapeu	63	Background and Aims: Cardiometabolic disorders (CMD) arise from a constellation of features
 Many genetic loci have shown associations with individual CMD-related traits, but no investigations have focused on simultaneously identifying loci showing associations across al domains. We therefore sought to identify loci associated with risk across seven continuous CMD-related traits. Methods and Results: We conducted separate genome-wide association studies (GWAS) for systolic and diastolic blood pressure (SBP/DBP), hemoglobin A1c (HbA1c), low- and high- density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides (TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels o significance (N=145-333) for each trait, but only four loci (in/near <i>VEGFA</i>, <i>GRB14-COBLL1</i> <i>KLF14</i>, and <i>RGS19-OPRL1</i>) were associated with risk across all seven traits (P<5×10⁻⁸). We sought replication of these four loci in an independent set of seven traits (P<5×10⁻⁸). We sought replications (P<0.05) with all traits except DBP. Conclusions: Our analyses suggest that very few loci are associated in the same direction of r with traits representing the full spectrum of CMD features. We identified four such loci, and a understanding of the pathways between these loci and CMD risk may eventually identify fact that can be used to identify pathologic disturbances that represent broadly beneficial therapeu targets. 	64	such as increased adiposity, hyperlipidemia, hypertension and compromised glucose control.
66investigations have focused on simultaneously identifying loci showing associations across al67domains. We therefore sought to identify loci associated with risk across seven continuous68CMD-related traits.69Methods and Results: We conducted separate genome-wide association studies (GWAS) for70systolic and diastolic blood pressure (SBP/DBP), hemoglobin A1c (HbA1c), low- and high-71density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides72(TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels o73significance (N=145-333) for each trait, but only four loci (in/near VEGFA, GRB14-COBLL174KLF14, and RGS19-OPRL1) were associated with risk across all seven traits (P<5×10 ⁻⁸). We75sought replication of these four loci in an independent set of seven trait-specific GWAS meta-76analyses. GRB14-COBLL1 showed the most consistent replication, revealing nominally77significant associations (P<0.05) with all traits except DBP.	65	Many genetic loci have shown associations with individual CMD-related traits, but no
 domains. We therefore sought to identify loci associated with risk across seven continuous CMD-related traits. Methods and Results: We conducted separate genome-wide association studies (GWAS) for systolic and diastolic blood pressure (SBP/DBP), hemoglobin A1c (HbA1c), low- and high- density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides (TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels o significance (N=145-333) for each trait, but only four loci (in/near <i>VEGFA</i>, <i>GRB14-COBLL1</i> <i>KLF14</i>, and <i>RGS19-OPRL1</i>) were associated with risk across all seven traits (P<5×10⁻⁸). We sought replication of these four loci in an independent set of seven trait-specific GWAS meta- analyses. <i>GRB14-COBLL1</i> showed the most consistent replication, revealing nominally significant associations (P<0.05) with all traits except DBP. Conclusions: Our analyses suggest that very few loci are associated in the same direction of r with traits representing the full spectrum of CMD features. We identified four such loci, and a understanding of the pathways between these loci and CMD risk may eventually identify fact that can be used to identify pathologic disturbances that represent broadly beneficial therapeu targets. 	66	investigations have focused on simultaneously identifying loci showing associations across all
 CMD-related traits. Methods and Results: We conducted separate genome-wide association studies (GWAS) for systolic and diastolic blood pressure (SBP/DBP), hemoglobin A1c (HbA1c), low- and high- density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides (TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels or significance (N=145-333) for each trait, but only four loci (in/near <i>VEGFA, GRB14-COBLL1</i> <i>KLF14</i>, and <i>RGS19-OPRL1</i>) were associated with risk across all seven traits (P<5×10⁻⁸). We sought replication of these four loci in an independent set of seven trait-specific GWAS meta- analyses. <i>GRB14-COBLL1</i> showed the most consistent replication, revealing nominally significant associations (P<0.05) with all traits except DBP. Conclusions: Our analyses suggest that very few loci are associated in the same direction of r with traits representing the full spectrum of CMD features. We identified four such loci, and a understanding of the pathways between these loci and CMD risk may eventually identify fact that can be used to identify pathologic disturbances that represent broadly beneficial therapeu targets. 	67	domains. We therefore sought to identify loci associated with risk across seven continuous
69 Methods and Results : We conducted separate genome-wide association studies (GWAS) for 70 systolic and diastolic blood pressure (SBP/DBP), hemoglobin A1c (HbA1c), low- and high- 71 density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides 72 (TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels o 73 significance (N=145-333) for each trait, but only four loci (in/near <i>VEGFA</i> , <i>GRB14-COBLL1</i> 74 <i>KLF14</i> , and <i>RGS19-OPRL1</i>) were associated with risk across all seven traits (P<5×10 ⁻⁸). We 75 sought replication of these four loci in an independent set of seven trait-specific GWAS meta- 76 analyses. <i>GRB14-COBLL1</i> showed the most consistent replication, revealing nominally 77 significant associations (P<0.05) with all traits except DBP. 78 Conclusions : Our analyses suggest that very few loci are associated in the same direction of r 79 with traits representing the full spectrum of CMD features. We identified four such loci, and a 80 understanding of the pathways between these loci and CMD risk may eventually identify fact 81 that can be used to identify pathologic disturbances that represent broadly beneficial therapeu 82 targets.	68	CMD-related traits.
70systolic and diastolic blood pressure (SBP/DBP), hemoglobin A1c (HbA1c), low- and high-71density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides72(TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels o73significance (N=145-333) for each trait, but only four loci (in/near VEGFA, GRB14-COBLL174 $KLF14$, and $RGS19$ -OPRL1) were associated with risk across all seven traits (P<5×10 ⁻⁸). We75sought replication of these four loci in an independent set of seven trait-specific GWAS meta-76analyses. GRB14-COBLL1 showed the most consistent replication, revealing nominally77significant associations (P<0.05) with all traits except DBP.	69	Methods and Results: We conducted separate genome-wide association studies (GWAS) for
71density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides72(TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels o73significance (N=145-333) for each trait, but only four loci (in/near <i>VEGFA, GRB14-COBLL1</i> 74 <i>KLF14</i> , and <i>RGS19-OPRL1</i>) were associated with risk across all seven traits (P<5×10 ⁻⁸). We75sought replication of these four loci in an independent set of seven trait-specific GWAS meta-76analyses. <i>GRB14-COBLL1</i> showed the most consistent replication, revealing nominally77significant associations (P<0.05) with all traits except DBP.	70	systolic and diastolic blood pressure (SBP/DBP), hemoglobin A1c (HbA1c), low- and high-
72(TGs) in the UK Biobank (N=356,574-456,823). Multiple loci reached genome-wide levels or73significance (N=145-333) for each trait, but only four loci (in/near <i>VEGFA</i> , <i>GRB14-COBLL1</i> 74 <i>KLF14</i> , and <i>RGS19-OPRL1</i>) were associated with risk across all seven traits ($P<5\times10^{-8}$). We75sought replication of these four loci in an independent set of seven trait-specific GWAS meta-76analyses. <i>GRB14-COBLL1</i> showed the most consistent replication, revealing nominally77significant associations ($P<0.05$) with all traits except DBP.78Conclusions: Our analyses suggest that very few loci are associated in the same direction of r79with traits representing the full spectrum of CMD features. We identified four such loci, and a80understanding of the pathways between these loci and CMD risk may eventually identify fact81that can be used to identify pathologic disturbances that represent broadly beneficial therapeu82targets.	71	density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides
73significance (N=145-333) for each trait, but only four loci (in/near VEGFA, GRB14-COBLL174 $KLF14$, and $RGS19$ -OPRL1) were associated with risk across all seven traits (P<5×10 ⁻⁸). We75sought replication of these four loci in an independent set of seven trait-specific GWAS meta-76analyses. GRB14-COBLL1 showed the most consistent replication, revealing nominally77significant associations (P<0.05) with all traits except DBP.	72	(TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels of
 <i>KLF14</i>, and <i>RGS19-OPRL1</i>) were associated with risk across all seven traits (P<5×10⁻⁸). We sought replication of these four loci in an independent set of seven trait-specific GWAS meta- analyses. <i>GRB14-COBLL1</i> showed the most consistent replication, revealing nominally significant associations (P<0.05) with all traits except DBP. Conclusions: Our analyses suggest that very few loci are associated in the same direction of r with traits representing the full spectrum of CMD features. We identified four such loci, and a understanding of the pathways between these loci and CMD risk may eventually identify fact that can be used to identify pathologic disturbances that represent broadly beneficial therapeu targets. 	73	significance (N=145-333) for each trait, but only four loci (in/near VEGFA, GRB14-COBLL1,
 sought replication of these four loci in an independent set of seven trait-specific GWAS meta- analyses. <i>GRB14-COBLL1</i> showed the most consistent replication, revealing nominally significant associations (P<0.05) with all traits except DBP. Conclusions: Our analyses suggest that very few loci are associated in the same direction of r with traits representing the full spectrum of CMD features. We identified four such loci, and a understanding of the pathways between these loci and CMD risk may eventually identify fact that can be used to identify pathologic disturbances that represent broadly beneficial therapeu targets. 	74	<i>KLF14</i> , and <i>RGS19-OPRL1</i>) were associated with risk across all seven traits ($P < 5 \times 10^{-8}$). We
 analyses. <i>GRB14-COBLL1</i> showed the most consistent replication, revealing nominally significant associations (P<0.05) with all traits except DBP. Conclusions: Our analyses suggest that very few loci are associated in the same direction of r with traits representing the full spectrum of CMD features. We identified four such loci, and a understanding of the pathways between these loci and CMD risk may eventually identify fact that can be used to identify pathologic disturbances that represent broadly beneficial therapeu targets. 	75	sought replication of these four loci in an independent set of seven trait-specific GWAS meta-
 significant associations (P<0.05) with all traits except DBP. Conclusions: Our analyses suggest that very few loci are associated in the same direction of r with traits representing the full spectrum of CMD features. We identified four such loci, and a understanding of the pathways between these loci and CMD risk may eventually identify fact that can be used to identify pathologic disturbances that represent broadly beneficial therapeu targets. 	76	analyses. GRB14-COBLL1 showed the most consistent replication, revealing nominally
78 Conclusions: Our analyses suggest that very few loci are associated in the same direction of r 79 with traits representing the full spectrum of CMD features. We identified four such loci, and a 80 understanding of the pathways between these loci and CMD risk may eventually identify fact 81 that can be used to identify pathologic disturbances that represent broadly beneficial therapeu 82 targets.	77	significant associations (P<0.05) with all traits except DBP.
 with traits representing the full spectrum of CMD features. We identified four such loci, and a understanding of the pathways between these loci and CMD risk may eventually identify fact that can be used to identify pathologic disturbances that represent broadly beneficial therapeu targets. 	78	Conclusions: Our analyses suggest that very few loci are associated in the same direction of risk
 understanding of the pathways between these loci and CMD risk may eventually identify fact that can be used to identify pathologic disturbances that represent broadly beneficial therapeu targets. 	79	with traits representing the full spectrum of CMD features. We identified four such loci, and an
81 that can be used to identify pathologic disturbances that represent broadly beneficial therapeu82 targets.	80	understanding of the pathways between these loci and CMD risk may eventually identify factors
82 targets.	81	that can be used to identify pathologic disturbances that represent broadly beneficial therapeutic
	82	targets.

83

84 Key words: GWAS, cardiometabolic disease, pleiotropy, risk alleles, fat distribution

It is made available under a CC-BY-NC-ND 4.0 International license .

85 Introduction

86 Cardiometabolic risk, the chance of developing type 2 diabetes (T2D), cardiovascular disease 87 (CVD) and/or stroke, is typically assessed through measures of adiposity, glucose control, lipid 88 metabolism, and blood pressure [1]. The clustering of these risk factors has been termed CMD 89 and is defined by The American College of Cardiology as the presence of hypertension, poor 90 glucose control, dyslipidemia, and abdominal obesity [2]. Recent data from the National Health 91 and Nutrition Examination Survey (NHANES) indicate that among US adults, almost 90% of 92 those with obesity, 50% with overweight and 25% of those at a normal weight met criteria for 93 elevated risk in at least of these indicators [3]. While individual measures of cardiometabolic risk 94 are linked with the development of CVD and T2D, studies are not unified in identifying which 95 specific measures convey the greatest risk for these outcomes [4, 5]. Where evidence does 96 strongly converge is in showing that the number of cardiometabolic risk factors is directly 97 proportional to the risk of developing endpoints such as T2D, CVD, and for predicting mortality 98 [6].

99 Each CMD feature results from a complex interplay between host genetics and lifestyle factors. Health behaviors such as physical activity and good dietary habits are associated with 100 101 protection across multiple cardiometabolic risk factors [7], suggesting at least a partially shared 102 behavioral etiology underlying CMD traits. However, the role that genetics plays in any shared 103 etiology between CMD traits is not well understood[8, 9]. For example, only two loci have 104 previously been identified as being implicated across T2D and cardiovascular disease: 105 *CDKN2A/B* and *IRS1*[9, 10]. Identifying those genetic factors that convey risk across multiple 106 CMD traits may increase our understanding of why risk factor clustering is not uniform across 107 individuals, and further help identify those whose overall CMD profile suggests a greater risk of

It is made available under a CC-BY-NC-ND 4.0 International license .

108	T2D and CVD and whom may especially benefit from behavioral interventions [11]. All CMD
109	indicators show significant heritability [12, 13], with modest genetic correlations in the range of
110	.15, suggesting both shared and measure-specific genetic loci across all traits associated with
111	CMD [14, 15]. In addition, a small number of loci have been identified that increase the risk for
112	one indicator (e.g., low-density lipoprotein cholesterol) but decrease the risk for another (e.g.,
113	glucose control [16-19]), mirroring some of the therapeutic effects of statins which reduce
114	dyslipidemia but convey a slightly increased risk for T2D [20-22]. However, we are not aware of
115	any studies that seek to identify variants associated with all the cardiometabolic risk factors
116	forming the features of CMD. The identification of such loci, if they exist, may help identify
117	underlying etiological pathways shared across many risk factors, improve our risk stratification
118	efforts and provide information on targets for therapeutics which, by seeking to address multiple
119	CMD risk factors, may have a broader range of beneficial clinical changes [23-25].
120	The present study aims to identify loci that are associated with each of seven
121	cardiometabolic traits, representing the four features of CMD, in the same (risk predisposing)
122	direction. Using data from the UK Biobank, which allowed us to leverage large numbers of
123	individuals with both genetic data and phenotype data across multiple indicators of
124	cardiometabolic disease, we took a genome-wide approach to identify variants significantly
125	associated with each of glucose control, central adiposity, and multiple measures of lipid
126	metabolism, and blood pressure. We then validated any significant associations in the published
127	summary statistics from independent large-scale meta-analytic GWAS for each trait.
128	
129	
120	

It is made available under a CC-BY-NC-ND 4.0 International license .

131

132 Methods

133 Study Population

134 The UK Biobank is a multi-center prospective cohort study of 500,000 adults ages 39 to 72 living in the UK. At each one of the 21 assessment centers, participants answered 135 136 questionnaires, were interviewed, and were physically measured as part of a baseline visit that 137 occurred between 2006 and 2010. A blood draw in a non-fasting state was performed for 138 subsequent genetic and biomarker analysis. Among the biomarkers tested were directly-139 measured circulating LDL-C, HDL-C, hemoglobin A1c (HbA1c), TG, and alanine 140 aminotransferase (ALT). The UK Biobank was approved by the National Information 141 Governance Board for Health and Social Care and the National Health Service North West 142 Multicentre Research Ethics Committee. All participants provided informed consent. Prevalent 143 T2D was defined according to the following criteria: 1) self-reported T2D or generic diabetes in 144 verbal interviews, 2) over the age of 35 years at diagnosis, and 3) not using insulin within one 145 year of diagnosis, to exclude possible type-1 diabetes cases [26]. 146 147 Genotype data 148 DNA of participants was genotyped with the Affymetrix UK Biobank Axiom Array 149 (Santa Clara, CA, USA), except for 10% of participants genotyped with the Affymetrix UK

150 BiLEVE Axiom Array. Information about genotype imputation, principal components analysis,

and quality control procedures can be found elsewhere [27]. Briefly, individuals were excluded if

they exhibited unusually high heterozygosity, a high missing rate (>5%), or exhibited a

153 mismatch between genetically inferred sex and self-reported sex. SNPs were excluded from

It is made available under a CC-BY-NC-ND 4.0 International license .

- analyses based on Hardy Weinberg equilibrium ($p < 1 \times 10^{-6}$), high missing rate (>1.5%), low
- 155 minor allele frequency (<0.1%), or a low imputation accuracy (info<0.4).
- 156
- 157 GWAS and Genetic Correlations of Trait Measures

158 We first examined seven continuous cardiometabolic traits in the UK Biobank: HbA1c, 159 LDL-C, HDL-C, TGs, waist-to-hip ratio adjusted for BMI (WHRadjBMI), and SBP and DBP 160 adjusted for BMI. Although fasting glucose is a commonly used glycemic trait, since UKB 161 participants are not fasted at the time of blood draw, we chose to use HbA1c instead. This allows 162 us to achieve a similar sample size and power for each of the seven traits in the discovery 163 analysis. Although HbA1c does have some limitations, is it more stable and reflective of long-164 term glycemia than fasting glucose. For the analyses of TG and HDL-C, we excluded individuals 165 reporting cholesterol-lowering medications. For the analysis of LDL-C, we adjusted the values of 166 people reporting cholesterol-lowering medication, by dividing their LDL-C values by a 167 correction factor of 0.63. For the analysis of HbA1c, we excluded individuals with prevalent 168 T2D (see above). For the analyses of SBP and DBP, we obtained the mean values across two 169 manual measurements and adjusted for the effect of anti-hypertensive medications by adding 15 170 and 10 points to SBP and DBP, respectively, among individuals reported to be on anti-171 hypertensive medications (and an additional 2 measurements in a subset of individuals) [28]. We 172 used LD-score regression to estimate genetic correlations across all pairs of trait [29]. 173 174 **GWAS** Replication Associations

We replicated identified associations by examining summary statistics of previously
conducted large-scale GWAS of the same traits: LDL-C, HDL-C, and TG from the Global Lipids

It is made available under a CC-BY-NC-ND 4.0 International license .

177	Genetics Consortium (GLGC; n=188,577)[30], WHRadjBMI from the Genetic Investigation of
178	Anthropometric Traits (GIANT) consortium (n=224,459) [31], SBP and DBP from Genetic
179	Epidemiology Research on Adult Health and Aging (GERA) cohort (n=99,785) [32], and HbA1c
180	from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC; n= 123,665)
181	[33].
182	
183	Follow-up associations with CMD end points
184	We examined the association of the four identified SNPs with coronary artery disease
185	(CAD), T2D, and stroke, some of the major outcomes arising from CMD, using GWAS meta-
186	analysis results published by the Coronary Artery Disease Genome-wide Replication And Meta-
187	analysis (CARDIOGRAM; n= up to 185,000)[34], Diabetes Genetics Replication And Meta-
188	analysis (DIAGRAM; n= 898,130)[34], and MEGASTROKE (n= 521612) [35] consortia.
189	
190	Statistical analysis

All UK Biobank phenotypes were inverse-normalized prior to GWAS. Although this limits our ability to interpret effect sizes, it does allow us to both normalize the variables and to compare effect sizes across traits. GWAS was performed with BOLT-LMM software which implements a linear mixed model regression that includes a random effect consisting of all SNP genotypes other than the one being tested. [36] We included the following variables as covariates: age, age^2 , sex, center, genotyping chip, and the first 10 principal components. SNPs were selected if their beta coefficient had the same direction of effect (opposite direction for HDL-C) and a corresponding p-value $< 5 \times 10^{-8}$ for each of the seven traits. If several SNPs were within a 1 Mb region, we chose the one with the lowest p-value based on a multivariate analysis

It is made available under a CC-BY-NC-ND 4.0 International license .

200	conducted with metaCCA [37]. We also performed multiple-trait genetic colocalization using
201	the "hyprcoloc" package in R to identify the best candidate variant given a genomic region for
202	each locus, using a region \pm 250kb region around the lead SNP.[38] A posterior probability of
203	full colocalization (PPFC) threshold of 0.72 (e.g. alignment probability=0.85 and regional
204	probability=0.85) was considered. In the replication dataset, we examined SNPs identified in the
205	UK Biobank discovery set, and considered that a consistent direction of effect, and with p<0.05,
206	qualified as a replication, given the smaller sample sizes in the replication datasets.
207	
208	Results
209	UK Biobank GWAS
210	Phenotypic and genetic correlations among seven traits are shown in Supplementary
211	Figure 1. Both phenotypic and genetic correlations were generally weak, with the exception of
212	some correlations among some lipid traits and between SBP and DBP. In GWAS among UK
213	Biobank participants, we identified 16 SNPs at four loci associated at genome-wide significance
214	with each of seven quantitative traits in the same risk-conferring/protecting direction, in/near
215	VEGFA, GRB14-COBLL1, KLF14, and RGS19-OPRL1 (Table 1 and Figure 1). In sex-stratified
216	analyses, there were no genome-wide significant SNPs for each trait (Figure 1, Supplementary
217	Table 1). Colocalization analyses showed colocalization across all seven traits for the GRB14-
218	COBBL1 locus, across six traits for KLF14 and RGS19-OPRL1, and across five traits for VEGFA
219	(all PPFC>0.72; Supplementary Table 2).
220	

221 GWAS in replication samples

It is made available under a CC-BY-NC-ND 4.0 International license .

222	Among the four SNPs identified in UK Biobank, we found that all four exhibit the same
223	direction of risk effect across all seven traits, but do not reach p<0.05 across all traits, likely due
224	to the substantially smaller sample sizes in those studies as compared to the UK Biobank (Table
225	2).
226	
227	Follow-up associations with CMD end points and phenome-wide association study
228	We found directionally consistent associations of the four loci identified in UK Biobank
229	with T2D, CAD, and stroke, although not all associations achieved statistical significance,
230	particularly for stroke (Supplementary Table 3). In silico phenome-wide association analyses
231	(PheWAS) of these four loci revealed associations with fat distribution patterns and
232	cardiometabolic conditions and medications, with limited to no evidence of adverse associations
233	with other conditions (see Supplementary Tables 4-8).
234	
235	Discussion
236	This is the first study, of which we are aware, to take a broad and well-powered genome-
237	wide approach to simultaneously identifying genetic loci associated with seven cardiometabolic
238	risk factors representing the four domains of CMD. We observed only four loci that increase the
239	risk for all seven of our traits; raised TGs and LDL-C, lowered HDL-C, raised HbA1c, and
240	systolic and diastolic blood pressure. Given that multiple robust genetic associations have been
241	published for each of our seven traits individually, these findings suggest that loci which
242	influence all seven features CMD are less common, and much of the genetic etiology is trait-
243	specific.

It is made available under a CC-BY-NC-ND 4.0 International license .

244	We found four loci which simultaneously associated with risk across seven CMD traits at
245	genome-wide levels of significance. Although this is the first study, of which we are aware to
246	conduct discovery across all seven traits simultaneously, previous studies have identified
247	associations between loci in GRB14-COBLL1, and RGS19-OPRLI with each of our
248	cardiometabolic traits independently. The intergenic SNP rs13889216 in GRB14-COBLL1, or
249	the nearby SNP rs10195252 in GRB14 have previously been associated at genome-wide levels of
250	significance with WHR ratio (sometimes with a larger effect size in females) [31, 39, 40] and
251	levels of TGs [40-43], HDL-C [31, 40, 42-44] and LDL-C [31]. Other studies have associated
252	these SNPs with additional traits often used as indicators of cardiometabolic disease or
253	cardiometabolic disease risk, such as total cholesterol [43], T2D [31, 43, 45] and other indices of
254	glycemic control [31, 40, 41, 43], often at levels approaching genome-wide significance.
255	Similarly, rs8126001 found in the 5' UTR of OPRL1 and 2kb upstream from RGS19 has been
256	previously associated with TG levels [42], HDL-C [42], SBP[46] and WHRadjBMI as well as
257	waist circumference in UK Biobank [46, 47], although its most replicated associations to date
258	have been with alcohol use/abuse. Similarly, associations have been observed between variants
259	at KLF14 and VEGFA with both T2D [48] and HDL-C levels in large-scale GWAS [49]. Taken
260	together, these previous data suggest our analysis approach is robust, and supporting the notion
261	that our associations of each of these four loci with all seven traits is generalizable. In the light of
262	evidence showing that the number of cardiometabolic risk factors is directly proportional to the
263	risk of T2D, CVD and mortality [6], information that these loci associate with risk across
264	multiple traits could be seen to raise the importance of these loci to the risk of developing these
265	conditions when compared to loci which raise the risk profile of a fewer number of traits.

It is made available under a CC-BY-NC-ND 4.0 International license .

266 Understanding the mechanisms that link our four loci to CMD risk may yield insights 267 into the full clinical profile of CMD. In the broader literature, two of our loci show multiple 268 associations with mechanisms underlying, and/or patterns of, fat deposition. For example, 269 *KLF14* regulates the expression of several genes in adipose tissue, and has been associated with 270 favorable adiposity [50], and, in women with adipogenesis, shifts in central vs. gynoid adiposity, 271 and the shift in the number and size of adipocytes [51]. In turn, GRB14 and the GRB14-COBLL1 272 locus have both been associated with body fat distribution (reviewed in [52]), and variation in or 273 near GRB14-COBLL1 to alter gene expression in subcutaneous fat, and in omental but not 274 mesenteric visceral fat [53]. These findings suggest that at least some of our putative loci are 275 united by their associations with patterns of fat deposition – an unsurprising implication given 276 that fat deposition patterning has recently emerged as a stronger indicator of cardiometabolic risk 277 factor clustering than overall adiposity, particularly in women (e.g. [54, 55]). In both genders, 278 visceral fat is an indicator of increased cardiometabolic risk [54, 56-62], however in women 279 only, deposition of fat in the lower body (gluteal-femoral fat) is associated with protection from 280 CMD risk factors [59, 63] and their downstream endpoint of CVD [55]. Supporting the notion 281 that CMD risk alleles may operate through fat patterning, a genetic risk score associated with fat 282 deposition phenotypes such as WHR, gluteofemoral fat and abdominal fat volume, also 283 associated CMD traits, as well as T2D and CVD [64], and the protective associations of GRB14-284 *COBLL1* variants on adverse lipid profiles have been theorized to me mediated through 285 alterations in body fat distribution [52].

There are of course limitations to our findings. Our sample is comprised of individuals with European-ancestry and generalizations beyond this population are not advised. In addition, while the rationale for the current analyses was to identify loci which most increase the risk of

It is made available under a CC-BY-NC-ND 4.0 International license .

289 cardiometabolic disease by exerting effects across multiple risk indicators simultaneously, our 290 loci have not been widely associated with hard outcomes such as CVD, except for associations of 291 GRB14-COBLL1, KLF14, and VEGFA with T2D (Supplementary Table 4) [31, 43, 45]. 292 Finally, many of our loci have been observed to have sex-specific effects especially with regards 293 to associations with fat patterning [51, 53, 65], and our analyses suggested sex-specific 294 magnitudes of associations with the our seven CMD traits, we were not powered to detect these 295 through formal interaction analyses. Future research should address these limitations, and also 296 continue to examine the excess of risk associated with visceral fat and identify mechanisms 297 linking fat deposition and cardiometabolic risk. 298 These current findings suggest that from all loci known to affect CMD related traits, only 299 a few may have effects across multiple traits, which are strong enough to be readily detectable at 300 genome-wide levels of significance. Although the effect sizes of these naturally occurring 301 genetic variants are very small, they do not necessarily reflect the importance of the pathways 302 that they point to. Interventions may thus have a much larger, more clinically meaningful impact 303 than immediately apparent from the effect sizes of the SNP-risk factor associations used to 304 identify these pathways. This has been illustrated in the case of HMGCR and statins with LDL-C 305 [66, 67]. If these loci serve as an indicator of risk across the highest number of CMD features, 306 and if future research identifies pathways linking these loci to CMD, such as via changes in fat 307 patterning, this research may eventually give insights into the apeutic targets that will yield a 308 broader range of clinical improvement. 309

310 Acknowledgments

It is made available under a CC-BY-NC-ND 4.0 International license .

- 311 This research was conducted using the UK Biobank Resource under Application Number 15678.
- 312 We thank the participants and organizers of the UK Biobank. The authors would also like to
- 313 acknowledge the vital contributions of the GWAS consortia: GLGC, MAGIC, GIANT,
- 314 DIAGRAM, CARDIOGRAM, as well as all organizers and participants of individual
- 315 participating studies.
- 316

317 Disclosures

- 318 The authors have no relevant conflicts of interest to disclose.
- 319
- 320

It is made available under a CC-BY-NC-ND 4.0 International license .

321	References
323	[1] Sasson C, Eckel R, Alger H, Bozkurt B, Carson A, Daviglus M, et al. American Heart
324	Association Diabetes and Cardiometabolic Health Summit: Summary and Recommendations. J
325	Am Heart Assoc. 2018;7:e009271.
326	[2] Cardiology ACo. Cardiometabolic Initiatives. 2020.
327	[3] Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The
328	obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic
329	risk factor clustering: prevalence and correlates of 2 phenotypes among the US population
330	(NHANES 1999-2004). Archives of internal medicine. 2008;168:1617-24.
331	[4] Saydah S, Bullard KM, Imperatore G, Geiss L, Gregg EW. Cardiometabolic risk factors
332	among US adolescents and young adults and risk of early mortality. Pediatrics. 2013;131:e679-
333	e86.
334	[5] Danaei G, Lu Y, Singh GM, Carnahan E, Stevens GA, Cowan MJ, et al. Cardiovascular
335	disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors
336	from 1980 to 2010: a comparative risk assessment. Lancet Diabetes & Endocrinology. 2014.
337	[6] Reddigan JI, Ardern CI, Riddell MC, Kuk JL. Relation of physical activity to cardiovascular
338	disease mortality and the influence of cardiometabolic risk factors. Am J Cardiol.
339	2011;108:1426-31.
340	[7] Waxman A, World Health A. WHO global strategy on diet, physical activity and health.
341	Food Nutr Bull. 2004;25:292-302.
342	[8] Fernandes Silva L, Vangipurapu J, Laakso M. The "Common Soil Hypothesis" Revisited-
343	Risk Factors for Type 2 Diabetes and Cardiovascular Disease. Metabolites. 2021;11.

- 344 [9] Strawbridge RJ, van Zuydam NR. Shared Genetic Contribution of Type 2 Diabetes and
- 345 Cardiovascular Disease: Implications for Prognosis and Treatment. Curr Diab Rep. 2018;18:59.
- [10] Zhao W, Rasheed A, Tikkanen E, Lee JJ, Butterworth AS, Howson JMM, et al.
- 347 Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with
- 348 coronary heart disease. Nat Genet. 2017;49:1450-7.
- 349 [11] Joseph PG, Pare G, Anand SS. Exploring gene-environment relationships in cardiovascular
- 350 disease. Can J Cardiol. 2013;29:37-45.
- 351 [12] Vattikuti S, Guo J, Chow CC. Heritability and genetic correlations explained by common
- 352 SNPs for metabolic syndrome traits. PLoS Genet. 2012;8:e1002637.
- 353 [13] Jermendy G, Horvath T, Littvay L, Steinbach R, Jermendy AL, Tarnoki AD, et al. Effect of
- 354 genetic and environmental influences on cardiometabolic risk factors: a twin study. Cardiovasc
- 355 Diabetol. 2011;10:96.
- 356 [14] Povel C, Boer J, Feskens E. Shared genetic variance between the features of the metabolic
- 357 syndrome: heritability studies. Molecular Genetics and Metabolism. 2011;104:666-9.
- 358 [15] Zhang S, Liu X, Yu Y, Hong X, Christoffel KK, Wang B, et al. Genetic and environmental
- 359 contributions to phenotypic components of metabolic syndrome: a population-based twin study.
- 360 Obesity (Silver Spring). 2009;17:1581-7.
- [16] Klimentidis YC, Arora A, Newell M, Zhou J, Ordovas JM, Renquist BJ, et al. Phenotypic
- and genetic characterization of lower LDL-C and increased type-2 diabetes risk in the UK
- 363 Biobank. Diabetes. 2020.
- 364 [17] Lotta LA, Sharp SJ, Burgess S, Perry JR, Stewart ID, Willems SM, et al. Association
- 365 between low-density lipoprotein cholesterol–lowering genetic variants and risk of type 2
- diabetes: a meta-analysis. Jama. 2016;316:1383-91.

- 367 [18] Zhao W, Rasheed A, Tikkanen E, Lee JJ, Butterworth AS, Howson JMM, et al.
- 368 Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with
- 369 coronary heart disease. Nat Genet. 2017;49:1450-7.
- 370 [19] Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, et al. Exome-wide
- association study of plasma lipids in> 300,000 individuals. Nature genetics. 2017;49:1758-66.
- [20] Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk
- 373 of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet.
- 374 2010;375:735-42.
- [21] Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, et al. Statin use and
- 376 risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes
- 377 Research and Care. 2017;5.
- 378 [22] Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident
- 379 diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
- 380 JAMA. 2011;305:2556-64.
- 381 [23] King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be
- 382 approved? Revised estimates of the impact of genetic support for drug mechanisms on the
- 383 probability of drug approval. PLoS genetics. 2019;15:e1008489.
- [24] Plenge RM. Priority index for human genetics and drug discovery. Nat Genet.
- 385 2019;51:1073-5.
- 386 [25] Fang H, Consortium U-D, De Wolf H, Knezevic B, Burnham KL, Osgood J, et al. A
- 387 genetics-led approach defines the drug target landscape of 30 immune-related traits. Nat Genet.
- 388 2019;51:1082-91.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.13.21267561; this version posted December 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 389 [26] Yaghootkar H, Lotta LA, Tyrrell J, Smit RA, Jones SE, Donnelly L, et al. Genetic evidence
- 390 for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension, and heart
- disease. Diabetes. 2016;65:2448-60.
- 392 [27] Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
- resource with deep phenotyping and genomic data. Nature. 2018;562:203-9.
- 394 [28] Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide
- 395 association analysis identifies novel blood pressure loci and offers biological insights into
- 396 cardiovascular risk. Nature genetics. 2017;49:403.
- 397 [29] Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An atlas of
- 398 genetic correlations across human diseases and traits. Nat Genet. 2015;47:1236-41.
- 399 [30] Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery
- 400 and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274-83.
- 401 [31] Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, et al. New
- 402 genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518:187-96.
- 403 [32] Hoffmann TJ, Ehret GB, Nandakumar P, Ranatunga D, Schaefer C, Kwok P-Y, et al.
- 404 Genome-wide association analyses using electronic health records identify new loci influencing
- 405 blood pressure variation. Nature genetics. 2017;49:54.
- 406 [33] Wheeler E, Leong A, Liu CT, Hivert MF, Strawbridge RJ, Podmore C, et al. Impact of
- 407 common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in
- 408 ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Med.
- 409 2017;14:e1002383.

- 410 [34] Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive
- 411 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat
- 412 Genet. 2015;47:1121-30.
- 413 [35] Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al.
- 414 Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated
- 415 with stroke and stroke subtypes. Nat Genet. 2018;50:524-37.
- 416 [36] Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for biobank-
- 417 scale datasets. Nat Genet. 2018;50:906-8.
- 418 [37] Cichonska A, Rousu J, Marttinen P, Kangas AJ, Soininen P, Lehtimäki T, et al. metaCCA:
- 419 summary statistics-based multivariate meta-analysis of genome-wide association studies using
- 420 canonical correlation analysis. Bioinformatics. 2016;32:1981-9.
- 421 [38] Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, et al. A fast and efficient
- 422 colocalization algorithm for identifying shared genetic risk factors across multiple traits.
- 423 bioRxiv. 2019:592238.
- 424 [39] Randall JC, Winkler TW, Kutalik Z, Berndt SI, Jackson AU, Monda KL, et al. Sex-stratified
- 425 genome-wide association studies including 270,000 individuals show sexual dimorphism in
- 426 genetic loci for anthropometric traits. PLoS Genet. 2013;9:e1003500.
- 427 [40] Liu CT, Monda KL, Taylor KC, Lange L, Demerath EW, Palmas W, et al. Genome-wide
- 428 association of body fat distribution in African ancestry populations suggests new loci. PLoS
- 429 Genet. 2013;9:e1003681.
- 430 [41] Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, Steinthorsdottir V, et al. Meta-
- 431 analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in
- 432 the genetic basis of fat distribution. Nat Genet. 2010;42:949-60.

- 433 [42] Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et
- 434 al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with
- 435 risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS
- 436 medicine. 2020;17:e1003062.
- 437 [43] Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, et al.
- 438 Large-scale association analysis provides insights into the genetic architecture and
- 439 pathophysiology of type 2 diabetes. Nature genetics. 2012;44:981.
- 440 [44] Kanoni S, Masca NG, Stirrups KE, Varga TV, Warren HR, Scott RA, et al. Analysis with
- the exome array identifies multiple new independent variants in lipid loci. Hum Mol Genet.
- 442 2016;25:4094-106.
- 443 [45] Kooner JS, Saleheen D, Sim X, Sehmi J, Zhang W, Frossard P, et al. Genome-wide
- 444 association study in individuals of South Asian ancestry identifies six new type 2 diabetes
- 445 susceptibility loci. Nat Genet. 2011;43:984-9.
- 446 [46] Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, et al. Leveraging Polygenic
- 447 Functional Enrichment to Improve GWAS Power. Am J Hum Genet. 2019;104:65-75.
- 448 [47] Zhu Z, Guo Y, Shi H, Liu C-L, Panganiban RA, Chung W, et al. Shared genetic and
- 449 experimental links between obesity-related traits and asthma subtypes in UK Biobank. Journal of
- 450 Allergy and Clinical Immunology. 2020;145:537-49.
- 451 [48] Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2
- 452 diabetes susceptibility loci identified through large-scale association analysis. Nature genetics.
- 453 2010;42:579.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.13.21267561; this version posted December 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 454 [49] Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al.
- 455 Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-

456 13.

- 457 [50] Ji Y, Yiorkas AM, Frau F, Mook-Kanamori D, Staiger H, Thomas EL, et al. Genome-wide
- 458 and abdominal MRI data provide evidence that a genetically determined favorable adiposity
- 459 phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart
- 460 disease, and hypertension. Diabetes. 2019;68:207-19.
- 461 [51] Small KS, Todorčević M, Civelek M, Moustafa JSE-S, Wang X, Simon MM, et al.
- 462 Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on
- 463 adipocyte size and body composition. Nature genetics. 2018;50:572-80.
- 464 [52] Loos RJ, Kilpeläinen TO. Genes that make you fat, but keep you healthy. Journal of internal
 465 medicine. 2018;284:450-63.
- 466 [53] Lu Y, Day FR, Gustafsson S, Buchkovich ML, Na J, Bataille V, et al. New loci for body fat
- 467 percentage reveal link between adiposity and cardiometabolic disease risk. Nature
- 468 communications. 2016;7:1-15.
- 469 [54] Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat is an
- 470 independent predictor of all-cause mortality in men. Obesity. 2006;14:336-41.
- 471 [55] Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose
- tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the
- 473 population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed). 1984;289:1257-61.
- 474 [56] Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue
- and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia.
- 476 1976;12:563-71.

- 477 [57] Cassano PA, Segal MR, Vokonas PS, Weiss ST. Body fat distribution, blood pressure, and
- 478 hypertension. A prospective cohort study of men in the normative aging study. Ann Epidemiol.
- 479 1990;1:33-48.
- 480 [58] Seidell JC, Cigolini M, Deslypere JP, Charzewska J, Ellsinger BM, Cruz A. Body fat
- 481 distribution in relation to serum lipids and blood pressure in 38-year-old European men: the
- 482 European fat distribution study. Atherosclerosis. 1991;86:251-60.
- 483 [59] Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, et al. Body fat
- 484 distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health
- 485 Study. Am J Epidemiol. 1997;145:614-9.
- 486 [60] Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and
- 487 weight gain as risk factors for clinical diabetes in men. Diabetes care. 1994;17:961-9.
- 488 [61] Nazare J-A, Smith JD, Borel A-L, Haffner SM, Balkau B, Ross R, et al. Ethnic influences
- 489 on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and
- 490 cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity
- 491 and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. The American
- 492 journal of clinical nutrition. 2012;96:714-26.
- 493 [62] Demerath EW, Reed D, Rogers N, Sun SS, Lee M, Choh AC, et al. Visceral adiposity and
- 494 its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk
- 495 factor levels. The American journal of clinical nutrition. 2008;88:1263-71.
- 496 [63] Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Peripheral adiposity
- 497 exhibits an independent dominant antiatherogenic effect in elderly women. Circulation.
- 498 2003;107:1626-31.

- 499 [64] Lotta LA, Wittemans LBL, Zuber V, Stewart ID, Sharp SJ, Luan J, et al. Association of
- 500 Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes,
- 501 Coronary Disease, and Cardiovascular Risk Factors. JAMA. 2018;320:2553-63.
- 502 [65] Wu Y, Broadaway KA, Raulerson CK, Scott LJ, Pan C, Ko A, et al. Colocalization of
- 503 GWAS and eQTL signals at loci with multiple signals identifies additional candidate genes for
- 504 body fat distribution. Human molecular genetics. 2019;28:4161-72.
- 505 [66] Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random
- solution to lower low-density lipoprotein cholesterol on the risk of coronary heart disease
- 507 mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2×2 factorial Mendelian
- randomization study. J Am Coll Cardiol. 2015;65:1552-61.
- 509 [67] Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, et al. Association
- 510 Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2
- 511 Diabetes: A Meta-analysis. Jama. 2016;316:1383-91.
- 512

513 **Table 1**. SNPs with significant associations in initial UK Biobank GWAS

		GRB14-COBLL1			<i>KLF14</i> rs201632637:CTTTTT/C β SE p			RGS19-OPRL1 rs8126001: C/T β SE			VEGFA-C6orf223		
	$\frac{\beta}{\beta} \frac{\beta}{\beta} \frac{\beta}$			p							β SE		р. С/А
TG (mmol/L)	356,574	0.037	0.002	7.7E-63	0.032	0.002	1.8E-50	0.017	0.002	2.6E-15	-0.040	0.002	2.6E-76
LDL-C (mmom/L)	431,167	0.018	0.002	2.4E-21	0.018	0.002	6.9E-22	0.017	0.002	1.0E-18	-0.017	0.002	1.3E-18
HDL-C (mmol/L)	397,721	-0.028	0.002	1.8E-50	-0.031	0.002	5.8E-63	-0.012	0.002	7.1E-11	0.035	0.002	3.2E-80
HbA1c (mmol/mol)	417,018	0.012	0.002	2.5E-09	0.011	0.002	2.6E-08	0.012	0.002	1.4E-09	-0.020	0.002	2.8E-26
SBP (mmHg)	453,413	0.016	0.002	3.4E-16	0.015	0.002	8.3E-14	0.018	0.002	7.1E-19	-0.011	0.002	2.4E-08
DBP (mmHg)	453,413	0.015	0.002	1.7E-14	0.017	0.002	3.8E-17	0.012	0.002	3.7E-10	-0.016	0.002	1.1E-16
WHRadjBMI	456,823	0.026	0.002	3.4E-64	0.012	0.001	1.7E-15	0.013	0.001	3.1E-17	-0.037	0.001	5.0E-139
metacca-p				5.4E-220			2.1E-149			1.0E-60			0.0E+00

514 Abbreviations: DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; TG:

514Abbreviations: DBP: diastolic blood pressure; HDL-C: high-dem515triglycerides; WHRadjBMI: waist-to-hip ratio adjusted for BMI

		GRB14-COBLL1 rs13389219:C/T beta se p			<i>KLF14</i> rs11765979:A/C			RGS19-OPRL1 rs7271530: C/T			VE r	<i>VEGFA-C6orf223</i> rs998584: C/A		
	Sample size				beta	se	р	beta	se	р	beta	se	р	
TG (mg/dl)	n _{max} =177,782	0.0271	0.0034	2.60E-15	0.0247	0.0047	2.32E-07	0.009	0.0056	4.71E-02	0.0293	0.0037	3.42E-15	
LDL-C (mg/dl)	n _{max} =173,012	0.022	0.0037	9.89E-08	0.0111	0.0052	3.26E-02	0.0093	0.0064	2.31E-02	0.0005	0.004	0.9359	
HDL-C (mg/dl)	n _{max} =173,012	-0.0226	0.0035	4.54E-10	-0.0412	0.0048	3.11E-17	-0.0101	0.0059	9.65E-02	-0.026	0.0038	2.27E-11	
HbA1C (%)	n=123,665	0.0062	0.0018	4.28E-04	0.0033	0.0018	6.08E-02	0.0051	0.0019	6.21E-03	-0.0083	0.0024	4.92E-04	
SBP (mmHg)	n=99,785	0.122	NA	0.031	0.0863	NA	0.11	0.199	NA	7.70E-03	0.085	NA	0.23	
DBP (mmHg)	n=99,785	0.0634	NA	0.085	0.0248	NA	0.48	0.142	NA	3.50E-03	0.0707	NA	0.12	
WHRadjBMI	n=694,649	0.027	0.0035	3.20E-15	0.0088	0.0043	0.041	0.012	0.0045	7.70E-03	0.043	0.0038	1.10E-29	

516 Note: Nominally significant associations (P<.05) in bold, standard errors (SE) not available in the published summary statistics for blood pressure.

517 rs11765979 at *KLF14* was used as a proxy for rs201632637 (r^2 =0.94, CEU)

518 Abbreviations: DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood

519 pressure; TG: triglycerides; HHRadjBMI: waist-to-hip ratio adjusted for BMI

- 520 **Figure 1:** Radar plot showing association p-values for all four loci identified in UK Biobank in A) both men and women, B) women
- 521 only, and C) men only.

